Skip links

Tag: Oncology

ASCO Webinar Summary: Gastric Cancer

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01) ( https://meetinglibrary.asco.org/record/185492/abstract ) Author, Company: Kohei Shitara, MD Abstract Number: 4513 Indications: Advanced HER2+ gastric or gastroesophageal junctional adenocarcinoma Interventions: Enhertu (Trastuzumab deruxtecan) Background and

ASCO Webinar Summary: Pancreatic Cancer-II

Pharmacokinetically-guided 5-FU dose optimization within the preoperative folfoxiri regimen in resectable pancreatic cancer patients  (Link to full article)  Author, Company : Anna Vilalta, University of Navarra, Pamplona, Spain and others Abstract Number: 4636 Indications : resectable pancreatic cancer (PC) Interventions : 5-FU, folfoxiri Background and objectives: Patients having

ASCO Webinar Summary: Pancreatic Cancer

Liposomal irinotecan plus fluorouracil/leucovorin versus folfirinox as the second-line chemotherapy for patients with metastatic pancreatic cancer (Link for full article)  Author, Company : Hongjae Chon, MD, Korean Cancer Study Group (KCSG) Abstract Number: 4624 Indications : Metastatic pancreatic cancer (mPC) Interventions : Liposomal irinotecan plus fluorouracil/leucovorin, folfirinox Background

ASCO Goes Virtual 2020

American Society of Clinical Oncology(ASCO)is an organization which represents around 45,000 physicians of all oncology sub-specialities. It was founded in the year 1964. ASCO works extensively towards conquering cancer through its educational programmes, in-depth research, and patient care of utmost quality. ASCO organises an annual

Call Now Button 
Contact Us